This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Atacand (Candesartan) Real Life Study (Real Life)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: February 8, 2008
Last updated: December 1, 2010
Last verified: December 2010
This study is a Swedish historical cohort study in patients prescribed Atacand or Cozaar for hypertension by selected primary care centres. Data will be extracted anonymously from electronic medical records. In addition, data regarding morbidity and mortality will be collected by merging the cohort with the following national registries: the Hospital Discharge Register (Slutenvårdsregistret), the Cause of Death Register and the Heart Intensive Care Admission (RIKS-HIA)

Condition Intervention
Hypertension Drug: Candesartan Cilexetil Drug: Losartan

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: A REtrospective Study on the Effects of cAndesartan vs. Losartan on Blood Pressure, Health Care Consumption and cardiovascuLar Events In a "Real-liFe" GP sEtting in Sweden

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The primary efficacy objective is to investigate, on basis of 'first to event', the development of new cardiovascular diseases (CVD). [ Time Frame: 1999 - 2007 ]

Secondary Outcome Measures:
  • Cardiovascular disease states and procedures in the background and over the entire observation period will be identified by use of ICD-9 and ICD-10 coding for diseases of the cardiovascular system. Specifically are death, acute cardiovascular events, new [ Time Frame: 1999 - 2007 ]
  • Health care consumption will be assessed as contacts with health care providers, in-hospital time periods for cardiovascular disease states with associated therapeutic procedures, and times spent within various levels of care (e.g. ICU and general ward). [ Time Frame: 1999 - 2007 ]

Estimated Enrollment: 14000
Study Start Date: March 2008
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Drug: Candesartan Cilexetil
oral once daily dose
Other Name: ATACAND
Drug: Losartan
once daily oral dose
Other Name: COZAAR


Ages Eligible for Study:   17 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Eligible subjects are all patients found in EPS systems at the participating centres, who were prescribed candesartan (ATC-C09CA06) or losartan (C09CA01) for hypertension from 1 January 1999 - 31 December 2004 inclusive. The first found prescription is designated as index.

Inclusion Criteria:

  • Recorded blood pressure prior to therapy of > 140 and/or 90 mmHg
  • Diagnosed as hypertensive within 15 months
  • First prescription of Cozaar or Atacand between 1 January 1999 and 31 December 2007, inclusive

Exclusion Criteria:

  • Previous prescription within 15 months any drug from the ATC groups C02, C03, C07 - C09 inclusive
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00620178

Research Site
Uppsala, Sweden
Sponsors and Collaborators
Principal Investigator: Jan Stålhammar, MD Eriksbergs vårdcentral
  More Information

Responsible Party: Anders Ljunggren, MD, AstraZeneca Identifier: NCT00620178     History of Changes
Other Study ID Numbers: NIS-CSE-ATA-2008/1
Study First Received: February 8, 2008
Last Updated: December 1, 2010

Keywords provided by AstraZeneca:
blood pressure
cardiovascular disease
health care consumption

Additional relevant MeSH terms:
Candesartan cilexetil
Anti-Arrhythmia Agents
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017